PTPA and central nervous system cancer: Gene deletion, missense or nonsense mutation, and frameshifts are reported as PP2A-deactivating mechanisms in gliomas [5,14,60], however loss of heterozygosity (LOH) resulting in homozygous deletion of PP2A structural subunits (PPP2R1A and PPP2R1B) is less frequent than in other cancer types.